Big picture - Why invest in Kazia Therapeutics Ltd
Kazia Therapeutics Ltd Snapshot
Kazia is a new company, with great potential in its pipeline, a clear strategy to realise value for shareholders, and a lean team with the experience and expertise to deliver benefit to patients.
GDC-0084 is a novel targeted therapy that modulates the PI3K pathway. Kazia has licensed GDC-0084 from Genentech and is developing it as a potential treatment for glioblastoma. Investigator led clinical studies are also underway for patients with DIPG and breast cancer which has metastasised to the brain.
Cantrixil is a first-in-class development candidate which targets the entire spectrum of cancer cells, including tumour-initiating cells thought to cause cancer recurrence. Cantrixil is currently being developed for treatment of ovarian cancer and is being trialled in hospitals across Australia and the United States under an Investigational New Drug application which was approved by the US FDA in 2016.
Last updated 29th April 2019
Chairman & Non-Executive Director
BSC (Hons), C.DIR
Mr Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and is currently Chairman of e-Therapeutics plc (LSE:ETX), Redx Pharma plc (LON:REDX) and Biomer Technology Limited.
During his career, Mr Ross has held senior positions at multinational companies, Sandoz AG, Hoffman La Roche, and Celltech Group PLC and been a Chairman, CEO and Director of several biotech companies. He is a qualified Chartered Director and former Vice Chairman of the Council of Royal Holloway, London University.
Mr Ross was appointed as a director of the Company in July 2015 and is considered to be an independent director.
Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales and Marketing and was a member of the company’s executive committee. He previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly.
During his career with Lilly, Mr Carmine held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea. He is currently Chairman and CEO of HaemaLogiX Pty Ltd, a Sydney-based privately owned biotech.
Mr Carmine was appointed as a director of the Company in June 2015 and is considered to be an independent director.
Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.
Mr Coffey is a registered company auditor and audits a number of large private companies as well as a number of not-for-profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of two private ancillary funds (PAFs).
Mr Coffey was appointed as a director to the Company in November 2012 and is considered to be an independent director.
Dr James Garner
Chief Executive Officer & Executive Director
MA, MBA, MBBS, BSC (Hons), MAICD
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.
Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore. Dr Garner is a member of the Australian Institute of Company Directors.
CA, GAICD, BSC (Hons)
Kate has over 20 years’ experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment.
In addition to her role at Kazia, Kate is a Non-Executive Director and Chair of the Audit Committee of CountPlus Limited (ASX:CUP), Elmo Software Limited (ASX:ELO) and Seeing Machines Limited (AIM:SEE), as well as being a member of other Committees of those boards.
Kate is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors.
Last updated 29th April 2019